November 2020 EGRP Cancer Epidemiology News

EGRP Cancer Epidemiology News


Survivorship Activities of the National Cancer Institute

As of January 2019, it is estimated that there are 16.9 million cancer survivors in the United States. This represents approximately 5.0% of the population. The number of cancer survivors is projected to increase to 21.7 million by 2029 and to 26.1 million by 2040.

In order to address the unique needs of the growing cancer survivor population, NCI and the Division of Cancer Control and Population Sciences (DCCPS) remain focused on supporting cancer survivorship research through more than 20 funding opportunity announcements and more than 100 active grants. See below for more NCI- and DCCPS-sponsored activities that promote cancer survivorship research.

Dr. Emily Tonorezos Joins NCI as Director of the Office of Cancer Survivorship

Emily S. Tonorezos, M.D., M.P.H., recently joined NCI’s Division of Cancer Control and Population Sciences (DCCPS) as Director of the Office of Cancer Survivorship (OCS). Prior to her appointment at NCI, Dr. Tonorezos served as Director of the Adult Long-Term Follow-Up Program at the Memorial Sloan Kettering Cancer Center and the Weill Cornell Medical College. Her research focuses on cardiometabolic consequences of cancer therapy, childhood and young adult cancer survivorship, diet and nutrition, and care coordination for this population. Dr. Tonorezos was also co-leader of the International Guideline Harmonization Group for the metabolic syndrome guidelines, and she led a recent international effort to develop recommendations for adult survivors of heritable retinoblastoma.

EGRP’s Clinical and Translational Epidemiology Branch

The Epidemiology and Genomics Research Program (EGRP) in DCCPS supports research in human populations to understand determinants of cancer occurrence and outcomes and to translate these findings to clinical and public health interventions. Within EGRP, the Clinical and Translational Epidemiology Branch (CTEB) stimulates, promotes, and supports cancer epidemiologic research to identify clinical, genomic, and lifestyle factors that improve outcomes for cancer survivors. Areas of particular interest to CTEB include, but are not limited to:

Cancer Survivorship Webinars, Including a New Series

EGRP supports several webinar series that include the topic of cancer survivorship.

Funding Opportunity Announcements Related to Cancer Survivorship Research

NCI-sponsored Funding Opportunity Announcements (FOAs) related to cancer survivorship research include but are not limited to:

For more funding opportunities related to cancer survivorship research, visit the DCCPS funding opportunities webpage.

To learn more about cancer survivorship research resources in DCCPS, please visit the Office of Cancer Survivorship’s website. If you would like to speak with program staff specializing in various aspects of cancer survivorship research, view the list of survivorship program contacts.

Funding Opportunities and Notices of Special Interest

  • Notices of Special Interest (NOSI):
    • Availability of Administrative Supplements to Adapt/Repackage Visualization Methods for Enhancing Cancer Moonshot Data (NOT-CA-21-008)
    • Administrative Supplement for Research and Capacity Building Efforts Related to Bioethical Issues (Admin Supp Clinical Trial Optional) (NOT-OD-21-020)
    • Academy of Finland (AKA) – National Institutes of Health (NIH) Partnership Program (NOT-OD-21-021
  • Notice of NIH Participation in Smart Health and Biomedical Research in the Era of Artificial Intelligence and Advanced Data Science (NOT-OD-21-011)
  • Discovery of the Genetic Basis of Childhood Cancers and of Structural Birth Defects: Gabriella Miller Kids First Pediatric Research Program (X01, Clinical Trial Not Allowed)
  • NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00, Independent Basic Experimental Studies with Humans Required; K99/R00, Independent Clinical Trial Not Allowed; K99/R00, Independent Clinical Trial Required)
  • Pilot Projects Enhancing Utility and Usage of Common Fund Data Sets (R03, Clinical Trial Not Allowed)
  • Cancer Prevention and Control Clinical Trials Grant Program (R01, Clinical Trial Required)
  • Stephen I. Katz Early Stage Investigator Research Project Grant (R01, Clinical Trial Not Allowed; R01, Basic Experimental Studies with Humans Required)
  • Research to Reduce Morbidity and Improve Care for Pediatric, and Adolescent and Young Adult (AYA) Cancer Survivors (R01, Clinical Trial Optional; R21, Clinical Trial Optional)
  • Addressing the Etiology of Health Disparities and Health Advantages Among Immigrant Populations (R01, Clinical Trial Not Allowed)
  • Addressing Health Disparities among Immigrant Populations through Effective Interventions (R01, Clinical Trial Optional)
  • Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21, Clinical Trial Not Allowed)
  • Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33, Clinical Trial Not Allowed)
  • Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R21, Clinical Trial Not Allowed)
  • Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33, Clinical Trial Not Allowed)
  • Cancer Research Education Grants Program:
    • Curriculum or Methods Development (R25, Clinical Trial Not Allowed)
    • Courses for Skills Development (R25, Clinical Trial Not Allowed)
    • Research Experiences (R25, Clinical Trial Not Allowed)
  • Notices of Intent to Publish Funding Opportunities Announcement for Nutrition for Precision Health, powered by the All of Us Research Program:
    • Artificial Intelligence for Multimodal Data Modeling and Bioinformatics Center (U54, Clinical Trial Not Allowed)
    • Metabolomics and Clinical Assays Center (U24)
    • Microbiome and Metagenomics Center (U24, Clinical Trial Not Allowed)
    • Dietary Assessment Center (U24, Clinical Trial Optional)
    • Clinical Centers (UG1, Clinical Trial Required)
    • Research Coordinating Center (U24, Clinical Trial Not Allowed)
  • Research Supplements to Promote Diversity in Health-Related Research (Admin Supp, Clinical Trial Not Allowed)

Grants Policy Notices

  • Extended Guidance for Applicants Preparing Applications During the COVID-19 Pandemic (NOT-OD-21-026)
  • Final NIH Policy for Data Management and Sharing (NOT-OD-21-013)
  • Supplemental Information to the NIH Policy for Data Management and Sharing:
    • Elements of an NIH Data Management and Sharing Plan (NOT-OD-21-014)
    • Allowable Costs for Data Management and Sharing (NOT-OD-21-015)
    • Selecting a Repository for Data Resulting from NIH-Supported Research (NOT-OD-21-016)
  • NIH Implementation of the Revised Federal-wide Research Terms and Conditions (NOT-OD-21-029)

Request for Information (RFI)

  • Request for Information (RFI): Inviting Comments and Suggestions on the NIH-Wide Strategic Plan for COVID-19 Research (NOT-OD-21-018)

Leadership Opportunity

NIH Blog Posts

Stay Connected

Subscribe for Updates

Subscribe
You can subscribe and unsubscribe at any time by entering your email address and selecting your preferences on the page that follows.

Subscribe to the E-Newsletter

Follow Us on Twitter

Need Help?

EGRP staff can answer questions on grant funding, policies, and research resources. If you do not know who to contact we will do our best to connect you with someone who can help you.

Email Us
(240) 276-6730